Browse by Series:

FDA Approval in ALL, Priority Reviews in CML and Breast Cancer, and More

Gina Columbus
Published: Monday, Jul 17, 2017



Gina Columbus reports on an FDA approval in acute lymphoblastic leukemia, priority reviews in chronic myeloid leukemia and breast cancer, ODAC recommendations in ALL and and acute myeloid leukemia, and a clinical hold on 3 multiple myeloma trials.
Slider Left
Slider Right


Gina Columbus reports on an FDA approval in acute lymphoblastic leukemia, priority reviews in chronic myeloid leukemia and breast cancer, ODAC recommendations in ALL and and acute myeloid leukemia, and a clinical hold on 3 multiple myeloma trials.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x